Skip to main content

Advertisement

Table 8 TEAEs by age group in the dose-optimization phase while receiving LDX with an incidence of ≥10% in the dose-optimization and/or crossover phase

From: Efficacy and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: sex and age effects and effect size across the day

AE-Preferred Term Dose-Optimization Phase
  6 to 9 year olds 10 to 12 year olds
  (n = 48) (n = 81)
  n (%) n (%)
Any AE 43 (89.6) 67 (82.7)
Abdominal pain upper 8 (16.7) 12 (14.8)
Affect lability 7 (14.6) 6 (7.4)
Anorexia 5 (10.4) 2 (2.5)
Decreased appetite 23 (47.9) 38 (46.9)
Headache 9 (18.8) 13 (16.0)
Insomnia 17 (35.4) 18 (22.2)
Irritability 7 (14.6) 14 (17.3)